Welcome to the
EVER Pharma Webinar
Platform.
We are happy to have you here!
Cerebrolysin’s evidence from TBI research – Treat early, reduce acute and post-acute complications
Treating secondary damage symptoms occurring short-and longterm after neurotrauma is an essential task of critical care specialists working in the ER and ICU. Pharmacological agents indicated to save lives after polytrauma or isolated head trauma are globally accepted medications. Cerebrolysin can nowadays be included into the globally acknowledged treatment bundles due to the strong evidence provided from the CAPTAIN trials. The speakers will discuss how the evidence lead to the inclusion into hospital-internal standard treatment strategies as well as first acknowledgement in important guidelines. Duration: 60 minutes Languages: Webinar will be held in English language incl. subtitles if requested. Furthermore...
Our Webinars
#tbi
Cerebrolysin’s evidence from TBI research – Treat early, reduce acute and post-acute complications
#stroke
Opening the vessel is not enough – Is Cerebrolysin the answer to improved longterm outcome after recanalization therapy?
On Demand
#tbi
Multidisciplinary Neurotrauma treatment - Panel Discussion about clinical reality and implementation strategies
#stroke
Treatment strategies for motor impaired stroke patients
#stroke
Cerebroprotective strategies in acute ischemic stroke - fiction or reality?
#stroke
The future of chronic stroke patient treatment - Interactive case discussions
#tbi
Neurorecovery - When evidence from the bench meets results at the bedside
#neurocognitive disorders
Treating cognitive decline after critical illnesses - A call to action
#stroke
New horizons improving gold standard therapy in acute stroke - Case discussions
#stroke
Get with the guidelines in post-stroke motor recovery - Expert panel discussion
#tbi
Evidence-based neurorecovery after stroke and TBI
#stroke